The proof is in the pudding: patient engagement in studying cannabidiol in mild cognitive impairment

The proof is in the pudding: patient engagement in studying cannabidiol in mild cognitive impairment

Abstract Background Patient engagement (PE) in clinical trials has gained importance yet remains uncommon, particularly in patients with mild cognitive impairment (MCI), a critical precursor to Alzheimer’s disease (AD). Cannabidiol (CBD) shows potential in slowing MCI progression due to its neuropro...

Descrizione completa

Dettagli Bibliografici
Autori principali: Antonia Keck, Julia-Sophia Scheuermann, Petra Scheerbaum, Elmar Graessel, Kirsten R. Müller-Vahl
Natura: Articolo
Lingua:English
Pubblicazione: BMC 2025-01-01
Serie:BMC Complementary Medicine and Therapies
Soggetti:
Mild cognitive impairment
Alzheimer’s disease
Cannabidiol
Cannabis-based medicine
Patient engagement
Patient and public involvement
Accesso online:https://doi.org/10.1186/s12906-025-04753-w

Accesso online

https://doi.org/10.1186/s12906-025-04753-w

Documenti analoghi